Get the Weekly Intelligence Brief — top committee picks every Sunday.
HSIC · NASDAQ · STOCK

Henry Schein

Healthcare Updated August 08, 2026
$88.16
52W $61.95 – $92.18
65/100
$10.04B
25.5
0.81
AI Committee Verdict
Buy
65/100
Conviction: High · 75% agreement · 4 analysts
+0.7%
-17.1%
0.04:1
High
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.

Is HSIC Bullish or Bearish?

Bullish. Innellis AI committee rates Henry Schein (HSIC) Buy with a composite score of 65/100 , based on 4 analysts with 75% agreement. Last updated August 08, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +9.94 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -10.06 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The primary driver is market regime is bullish (bull market -- normal position sizing). The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.

Bull & Bear Case

Bull Case
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
  • News sentiment is positive (+0.20 across 31 articles, 14d) — News
Bear Case
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 08, 2026
Overall Committee Score
65/100
Agreement
75%
Analysts
4
Conviction
High
Sector Rank
Top 18%
of 95 Healthcare peers
Growth Analyst neutral
58 / 100 · Moderate confidence
Moderate growth -- present but not remarkable
+ 4 consecutive earnings beats -- consistent execution
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst bullish
69 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
64 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 31 articles, 14d)
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 4 existing position pair(s) are highly correlated already
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 62.4 to 65.1.

Analyst-level changes:
  • Growth Analyst: score 52->58 (+6).
  • Value Analyst abstained (was neutral at 58).

Comparing 2026-08-07 to 2026-08-08 (1 day apart).

Technical Analysis

RSI (14)
60.6
Neutral
MACD Histogram
0.077
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$73.09
Resistance
$88.73
Bollinger %B
0.76
Inside Bands
Price vs Moving Averages
EMA 9
$87.46 Above
EMA 21
$86.28 Above
EMA 50
$83.56 Above
EMA 200
$77.57 Above

Fundamental Analysis

Valuation
52
Growth
61
Profitability
34
Financial Health
54
Cash Flow
70
Valuation
P/E Ratio 25.5×
P/B Ratio 3.17×
PEG Ratio 2.50
Dividend Yield 0.00%
52W High $92.18
52W Low $61.95
Quality & Growth
ROE 1226.5%
ROA 354.9%
Gross Margin 3031.2%
Operating Margin 569.0%
Revenue Growth YoY
Debt / Equity 1.21
AI Fundamental Assessment
P/E ratio of 25.5 (moderate relative to a 15-40x range); Price-to-book of 3.2x; PEG ratio of 2.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 12.3%; Return on assets of 3.5%; Net margin of 3.0%; Gross margin of 30.3%; Current ratio of 1.32 (tight short-term liquidity); Debt-to-equity of 1.21; Free cash flow per share is positive (4.75); Most recent quarter beat estimates by 0.7%; 4 consecutive earnings beats; EPS growth decelerating (-1.5% -> -3.8% QoQ); Average YoY EPS growth of 15.4%; Analyst estimates falling over recent quarters
Get the Full HSIC Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore HSIC Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime